Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jared Jagdeo

Procedural Dermatology Brooklyn, NY Medical Doctor

NPI 1992983456 CMS profile 226459

450 Clarkson Ave Fl 8, Brooklyn, NY 11203

Open in the dashboard

General payments

$362,232

687 records reported · program years 2019–2025

Research payments

$981

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$256,827 paid to institutions, not to them · program years 2020–2021

Through program year 2025, Jared Jagdeo of Brooklyn, NY is reported in the CMS Open Payments database as having received $362,232 across 687 general payments and $981 in research payments paid to them. Separately, studies naming them as principal investigator received $256,827 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 96th percentile of Procedural Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $94,477 198
2025 Research $981 1
2024 General $57,797 169
2023 General $43,854 110
2022 General $9,572 38
2021 General $1,426 21
2020 General $47,097 43
2019 General $108,009 108

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jared Jagdeo
  • Procedural Dermatology median
  • Middle half of Procedural Dermatology
  • National median

In program year 2025, general payments to Jared Jagdeo were reported at $94,477. Among 381 Procedural Dermatology profiles paid that year, the median was $592 and the middle half received between $144 and $1,778.

Show as a table
Year Jared Jagdeo Procedural Dermatology median Middle half National median
2019 $108,009 $454 $152–$1,260 $163
2020 $47,097 $243 $90–$835 $114
2021 $1,426 $337 $102–$1,128 $132
2022 $9,572 $443 $119–$1,654 $149
2023 $43,854 $583 $137–$1,838 $160
2024 $57,797 $611 $132–$1,835 $164
2025 $94,477 $592 $144–$1,778 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Sun Pharmaceutical Industries Inc. $95,826 106 payments
  2. Galderma Laboratories, L.P. $66,001 72 payments
  3. DUSA Pharmaceuticals, Inc. $49,377 34 payments
  4. Dermira, Inc. $39,890 35 payments
  5. Regeneron Healthcare Solutions, Inc. $33,941 57 payments
  6. Genzyme Corporation $20,800 31 payments
  7. Organon LLC $20,514 24 payments
  8. E.R. Squibb & Sons, L.L.C. $8,858 54 payments
  9. Dermavant Sciences, Inc. $8,015 40 payments
  10. Pfizer Inc. $7,398 17 payments
  11. Other $11,611 217 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Honoraria $137,260 35 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $115,633 33 payments
  3. Travel and Lodging $39,177 93 payments
  4. Consulting Fee $38,135 12 payments
  5. Food and Beverage $30,162 510 payments
  6. Compensation for serving as faculty or as a speaker for a medical education program $1,760 1 payment
  7. Education $105 3 payments
Products named General payments · program years 2019–2025
  1. LEVULAN KERASTICK $118,064 70 payments
  2. QBREXZA $39,890 35 payments
  3. NEMLUVIO $38,918 31 payments
  4. DUPIXENT Immunology $29,654 38 payments
  5. VTAMA $28,329 62 payments
  6. DUPIXENT Inflammation And Immunology $19,880 38 payments
  7. Odomzo $16,242 23 payments
  8. BLU-U $15,517 17 payments
  9. DUPIXENT Immunology And Inflammation $14,149 20 payments
  10. TREMFYA $3,131 36 payments
  11. Other $11,969 276 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Regeneron Pharmaceuticals, Inc. $981 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

13

Median for Dermatology: 534

Drug cost

$47,402

Median for Dermatology: $67,151

Branded share of claims

100%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 13 $47,402

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $11,431
  • GENZYME CORPORATION $5,473
$16,904 13 —
VTAMA
  • Dermavant Sciences, Inc. $6,626
$6,626 — —
LEVULAN KERASTICK
  • Sun Pharmaceutical Industries Inc. $6,260
$6,260 — —
TREMFYA
  • Janssen Biotech, Inc. $1,938
  • Janssen Scientific Affairs, LLC $102
$2,041 — —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $665
$665 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

688 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Procedural Dermatology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record